Citigroup Inc Gritstone Bio, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Citigroup Inc holds 142 shares of GRTS stock, worth $4. This represents 0.0% of its overall portfolio holdings.

Number of Shares

142

Previous 94,352 99.85%

Holding current value

Previous $58,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$0.45 - $0.71 $42,394 - $66,889	-94,210 Reduced 99.85%	142 $0
Q2 2024 Aug 12, 2024	BUY	$0.62 - $2.35 $47,995 - $181,918	77,412 Added 456.98%	94,352 $58,000
Q1 2024 May 10, 2024	BUY	$1.96 - $2.9 $8,261 - $12,223	4,215 Added 33.12%	16,940 $43,000
Q4 2023 Feb 09, 2024	BUY	$1.28 - $2.85 $14,721 - $32,777	11,501 Added 939.62%	12,725 $25,000
Q3 2023 Nov 09, 2023	SELL	$1.19 - $2.26 $31,443 - $59,715	-26,423 Reduced 95.57%	1,224 $2,000
Q2 2023 Aug 10, 2023	SELL	$1.66 - $3.03 $256,997 - $469,098	-154,818 Reduced 84.85%	27,647 $53,000
Q1 2023 May 11, 2023	BUY	$2.13 - $3.74 $92,471 - $162,368	43,414 Added 31.22%	182,465 $507,000
Q4 2022 Feb 09, 2023	BUY	$2.17 - $3.92 $294,809 - $532,559	135,857 Added 4253.51%	139,051 $479,000
Q3 2022 Nov 10, 2022	BUY	$2.46 - $4.75 $3,746 - $7,234	1,523 Added 91.14%	3,194 $8,000
Q2 2022 Aug 10, 2022	SELL	$1.77 - $4.34 $10,145 - $24,876	-5,732 Reduced 77.43%	1,671 $4,000
Q1 2022 May 12, 2022	SELL	$4.03 - $12.19 $839,541 - $2.54 Million	-208,323 Reduced 96.57%	7,403 $31,000
Q4 2021 Feb 10, 2022	BUY	$8.76 - $13.71 $1.85 Million - $2.89 Million	211,123 Added 4586.64%	215,726 $2.77 Million
Q3 2021 Nov 10, 2021	BUY	$6.41 - $13.54 $29,505 - $62,324	4,603 New	4,603 $50,000

Others Institutions Holding GRTS

# of Institutions

Shares Held

35.4M

Call Options Held

395K

Put Options Held

132K

View Full List

About Gritstone bio, Inc.

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

More about GRTS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account